Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Seroprevalence of Measles (Rubeola) Antibodies in Childhood Cancer Survivors.
Crom DB, Walters LA, Li Y, Liang J, Hijano DR, Mulrooney DA, Carmichael LA, Ford SL, Andrews SJ, Smith D, Hudson MM, Mandrell BN. Crom DB, et al. Among authors: ford sl. J Pediatr Hematol Oncol Nurs. 2024 May 7:27527530231221145. doi: 10.1177/27527530231221145. Online ahead of print. J Pediatr Hematol Oncol Nurs. 2024. PMID: 38715372
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Han K, Patel P, McCallister S, Rinehart AR, Gandhi Y, Spreen W, Landovitz RJ, Delany-Moretlwe S, Marzinke MA, McKeon T, Budnik P, van Wyk J, Ford SL. Han K, et al. Among authors: ford sl. Antimicrob Agents Chemother. 2024 May 6:e0147523. doi: 10.1128/aac.01475-23. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 38709006 Free article.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH, Capparelli EV, Calabrese K, Baltrusaitis K, Marzinke MA, McCoig C, Van Solingen-Ristea RM, Mathiba SR, Adeyeye A, Moye JH, Heckman B, Lowenthal ED, Ward S, Milligan R, Samson P, Best BM, Harrington CM, Ford SL, Huang J, Crauwels H, Vandermeulen K, Agwu AL, Smith-Anderson C, Camacho-Gonzalez A, Ounchanum P, Kneebone JL, Townley E, Bolton Moore C; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Gaur AH, et al. Among authors: ford sl. Lancet HIV. 2024 Apr;11(4):e211-e221. doi: 10.1016/S2352-3018(23)00300-4. Lancet HIV. 2024. PMID: 38538160 Clinical Trial.
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
Oka S, Holohan V, Shirasaka T, Choi JY, Kim YS, Chamay N, Patel P, Polli JW, Ford SL, Crauwels H, Garside L, D'Amico R, Latham C, van Solingen-Ristea R, Baugh B, van Wyk J. Oka S, et al. Among authors: ford sl. HIV Med. 2024 Mar;25(3):381-390. doi: 10.1111/hiv.13588. Epub 2023 Dec 26. HIV Med. 2024. PMID: 38147871
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P, Teichner P, Elliot E, Boffito M, Murray M, Polli JW, Baker M, Ford SL, Han K, Russu A, Crauwels H, D'Amico RD, Spreen WR, van Wyk J. Patel P, et al. Among authors: ford sl. Ther Adv Infect Dis. 2023 Dec 13;10:20499361231214626. doi: 10.1177/20499361231214626. eCollection 2023 Jan-Dec. Ther Adv Infect Dis. 2023. PMID: 38107552 Free PMC article. Review.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Han K, Gevorkyan H, Sadik Shaik J, Crauwels H, Leemereise C, Bontempo G, Win B, Chounta V, Seal C, DeMoor R, D'Amico R, Spreen WR, Ford SL. Han K, et al. Among authors: ford sl. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0078123. doi: 10.1128/aac.00781-23. Epub 2023 Dec 1. Antimicrob Agents Chemother. 2024. PMID: 38038460 Free PMC article.
99 results